ADMA Biologics, Inc.

NasdaqGM:ADMA

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💻 Telehealth

Location

United States

Market Cap

USD 4.24 B

Share Price

USD 17.74

Avg Daily Volume

3,513,149

Change (1 day)

-2.15%

Change (1 year)

65.64%

Change (YTD)

3.44%

ADMA Biologics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 33.10%

ADMA Biologics, Inc. Operating Income Margin is 33.10% for the Trailing 12 Months (TTM) ending March 31, 2025, a 111.73% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

ADMA Biologics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 15.63%, a -212.10% change year over year.
ADMA Biologics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -13.94%, a -77.41% change year over year.
ADMA Biologics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -61.73%, a -53.13% change year over year.
ADMA Biologics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -131.71%, a 5.46% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

NasdaqGM: ADMA

ADMA Biologics, Inc.

CEO	Mr. Adam S. Grossman
IPO Date	Oct. 17, 2013
Location	United States
Headquarters	465 State Route 17
Employees	685
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💻 Telehealth

Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.